Thank you to all patients, researchers, clinicians and partners who made this journey possible.

Learn more about IMMUcan's research, datasets and scientific outputs: immucan.eu

IMMUcan's clinical, molecular and imaging datasets will remain available through recognised repositories, creating a lasting resource for the global cancer research community and enabling future advances in immuno-oncology.

📊 30+ presentations at major international conferences
📚 A growing portfolio of publications
🔬 New insights into tumour–immune interactions
👩‍🔬 Support for the next generation of cancer researchers

Explore access: immucan.eu/how-to-colla...

Read the paper:
www.cell.com/cell-reports...

🧬 Better outcomes: immune-enriched, proliferative tumors
🚫 Poor prognosis: angiogenic, fibrotic, immune-excluded TMEs + PIK3CA alterations
🔄 Early resistance signals include PD-L1 downregulation and immunosuppressive macrophage infiltration

IMMUcan’s strength lies in its community — brilliant minds united to turn complex data into patient impact.

Huge thanks to all teams, coordinators & contributors driving this collaboration forward. 🙌

#IMMUcan #Collaboration #DataScience

Highlights included:
🔹 New molecular, cellular & clinical data — from spatial transcriptomics to plasma profiling
🔹 Cohort updates across breast, colorectal, renal, lung & head & neck cancers
🔹 Multi-modal data integration linking spatial & bulk omics